Avalo Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
1500 LIBERTY RIDGE DRIVE, WAYNE, PA, 19087
Mailing Address
1500 LIBERTY RIDGE DRIVE, WAYNE, PA, 19087
Phone
410-522-8707
Fiscal Year End
1231
EIN
450705648
Financial Overview
FY2025
$33.41M
Total Liabilities
$133.03M
Stockholders' Equity
$-5.84
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
Annual Reports
10-K
March 23, 2026
- Strategic licensing deals, notably AVTX-009 with Lilly, provide significant non-dilutive funding and external validation of their pipeline.
- A focused pipeline targeting serious inflammatory and autoimmune diseases with multiple drug candidates advancing through development.
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.